Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | NAMPT | P43490 | 3/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519190 | 0.98 | HDAC6 (0.61) | HDAC6L3MBTL3L3MBTL1HRH3NAMPT | |
| SCHEMBL4513210 | 0.97 | HDAC6 (0.64) | HDAC6L3MBTL3L3MBTL1HRH3NAMPT | |
| SCHEMBL4509076 | 0.96 | HDAC6 (0.65) | HDAC6L3MBTL3L3MBTL1HRH3NAMPT | |
| SCHEMBL4514344 | 0.94 | HDAC6 (0.67) | HDAC6L3MBTL3L3MBTL1NAMPTKEAP1 | |
| SCHEMBL4529449 | 0.94 | HDAC6 (0.67) | HDAC6L3MBTL3L3MBTL1NAMPTKEAP1 | |
| SCHEMBL4428062 | 0.94 | HDAC6 (0.60) | HDAC6L3MBTL3L3MBTL1HRH3NAMPT | |
| SCHEMBL4438426 | 0.93 | HDAC6 (0.62) | HDAC6L3MBTL3L3MBTL1HRH3NAMPT | |
| SCHEMBL4519157 | 0.89 | ACACB (0.51) | HDAC6L3MBTL3L3MBTL1HRH3KDM2B | |
| SCHEMBL4519155 | 0.89 | ACACB (0.51) | HDAC6L3MBTL3L3MBTL1HRH3KDM2B | |
| SCHEMBL4519768 | 0.89 | ACACB (0.51) | HDAC6L3MBTL3L3MBTL1HRH3KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | claimed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008109336-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HDAC6 848/4885L3MBTL3 2511/4885L3MBTL1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.